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Alterations of MUC2 Mucin in Colorectal
Adenocarcinoma

Abstract: MUC2 is a well-identified intestinal
mucin, present predominantly in the small
intestine and colon. It is known that
pathological alterations in the expression and
composition of this mucin occur in several
serious diseases related to epithelial surfaces,
e.g., carcinoma and colitis ulcerosa. In this
study, our aim was to find out whether there
are any specific alterations in the expression
and secretion of MUC2 in an adenomaadenocarcinoma sequence that has been
established as an in vitro model (1,2). The
adenoma-carcinoma sequence represents the
first example of the malignant progression of
human colonic adenoma cells in vitro (2,3).
Using a novel approach that we established

Introduction
An analysis of the pre-cancer stages is essential in
understanding the complex initiation and promotional
events involved in the development of carcinoma. It may
also provide an opportunity to detect malignancy before
early premalignant changes and alter the natural history
of carcinogenesis through earlier diagnosis.
Unfortunately, it is not always possible to detect precancerous stages of cancers in the human body. The
development of colorectal cancer is an excellent example
of the multistep nature of carcinogenesis. In colorectal
carcinogenesis a clear premalignant stage, adenomas
(benign epithelial tumours, sometimes called polyps) have
been recognised, and most colorectal cancers are thought
to originate from premalignant adenomas in what is often
called the adenoma-carcinoma sequence (5-7).
Colorectal mucosa, like the other epithelial surfaces, is
covered by a visco-elastic gel (mucus) whose biological
functions include lubrication, maintenance of tissue
hydration, and cytoprotection against proteases, pH
extremes, chemical irritants and biological agents. The

previously (4) ÐÐ the combination of density
gradient centrifugation and agarose gel
electrophoresisÐÐ we have characterised and
compared the cell layer and medium MUC2
mucins among the colonic cell lines
representing different stages of colorectal
carcinogenesis. The results indicate that the
expression and secretion of MUC2 mucin
decrease from adenoma to adenocarcinoma.
This is consistent with frequently
observations in in vivo carcinogenesis (5) and
strongly suggests that intestinal MUC2
mucins may be a useful marker for malignant
transformation.
Key Words: Mucins, MUC2, PC/AA cell line,
carcinogenesis, tumour markers.

molecules responsible for the rheological properties of
mucus are mucin glycoproteins produced from cells in the
epithelial surface layer and glands from the underlying
sub-mucosa. These extremely large macromolecules are
characterised by a very high molecular mass containing
>70% of their dry weight as carbohydrate in the form of
O-linked oligosaccharides linked to serine and threonine
residues in the mucin peptide.
So far a family of mucin genes (the MUC genes)
coding for at least 9 distinct members has been reported
(8-12). These mucin genes are located on several
chromosomes (9,10,13). Interestingly, there is a cluster
on 11p15.5 in the sequence telomere HRAS-MUC6MUC2-MUC5AC-MUC5B-IGF2 centromere (14). MUC1,
MUC2, MUC3 and MUC4 are commonly expressed in the
colon, with MUC2 representing the major gel-forming
secretory component (15-20).
Previously, we described an approach that allows the
study of the total population of MUC2 molecules, both
those inside the cell and those secreted into the culture
medium from a colonic cell line PC/AA, using two MUC2-
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specific antibody probes (4). In the present work,
employing the same procedure for several colonic cell
lines representing different stages of colorectal adenomacarcinoma sequence, we followed the expression and
secretion of MUC2 during the conversion from adenoma
to malignant transformants.
EXPERIMENTAL
Materials
Guanidinium chloride (GuHCl), goat anti-rabbit IgG
horseradish peroxidase conjugate, goat anti-mouse IgM
horseradish peroxidase and alkaline phosphatase
conjugate were purchased from the Sigma Chemical Co
(Poole, Dorset UK). Tween 20 and CsCl were from BDH
Ltd (Dagenham, Essex. UK). A stock solution of GuHCl
was treated with charcoal before use. Agarose UltraPURE
(electrophoresis grade) was from GIBCOBRL (Paisley,
Scotland). The enhanced chemiluminescence (ECL)
Western detection kit was from Amersham International
Plc (Buckinghamshire, UK).
Methods
Cell culture and collection of mucins
The PC/AA adenoma cell line was derived from a
single, large, colonic tubular adenoma 3-4 cm in diameter
that exhibited only mild dysplasia. The cells were
continuously passaged in vitro at 37¡C in 5% CO2 in air
and 3T3 feeder cells in collagen type IV-coated T25
flasks. The PC/AA cells at passage 8 used as a benign step
for the adenoma-carcinoma sequences in this study are
non-tumourogenic in nude mice, and have ultrastructural
characteristics of colonic cells (1). Isolation of the
clonogenic variant, designated AA/C1, and the malignant
phenotype AA/C1/SB10 is schematically represented in
Figure 1 (1-3).
The cell layers holding the same numbers of cells (2 x
107) were solubilised with 6M GuHCl containing 5mM
EDTA, 10mM Benzamidine, 5mM N-ethylmaleimide, 0.1
mg/ml soy bean trypsin inhibitor, and 1mM PMSF
proteinase inhibitors, and the media were mixed with an
equal volume of 6M GuHCl.
Preparation of reduced mucins
Reduced mucins were prepared following dialysis of
the whole mucins into GuHCl reduction buffer (6M
GuHCl/0.1M Tris/5mM EDTA, pH 8.0) and then treated
with 10mM DTT for 5h at 37¡C. Iodoacetamide was
added to a final concentration of 25mM and the mixture
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left in the dark overnight at room temperature.
Alternatively mucins were reduced on nitrocellulose
membranes after slot or Western blotting. In brief, the
blotted membrane was washed in distilled water for a
few minutes and incubated in urea or GuHCl reduction
buffer containing 10mM DTT at room temperature for
15 minutes. After removing the DTT solution, the
membrane was incubated in the same buffer containing
25mM iodoacetamide at room temperature for 10
minutes and then washed twice (5min) with distilled
water.
Antibodies
Monoclonal antibody 4F1 (IgM ascites, 1:1000) was a
kind gift from Dr. M. McGuckin (University of
Queensland, Australia). This antibody was raised to a
synthetic peptide corresponding to a single repeat of the
MUC2 tandem repeat (TR) and recognises two different
sites, TPTP and PTTT (21). These epitopes would be
expected to be covered by glycans in the mature MUC2
mucins; thus, this may only be a suitable probe for the
polypeptide. Polyclonal antiserum LUM2-3 was a kind gift
from Dr. I. Carlstedt (University of Lund, Sweden). This
antiserum was raised against a synthetic peptide
NGLQPVRVEDPDGC in the non-TR of the molecule
towards the C-terminus (22). When using LUM2-3 for
probing slot or Western blots of unreduced mucins, the
molecules are reduced on the membrane prior to
incubation with the antiserum, because its activity is
dramatically enhanced by reduction of disulphide bonds,
indicating that these epitopes are buried within tertiary
structural elements of the molecule. Therefore, this
antiserum is an effective probe for the reduced MUC2
subunit regardless of its state of O-glycosylation.
Isopycnic density-gradient centrifugation
The cell layer extracts and media were centrifuged at
a starting density of 1.40 g/ml in 4M GuHCl/CsCl using a
Beckman Ti70.1 rotor at 40 000 rpm for 68h at 15¡C.
Centrifuge tubes (13 ml) were then emptied manually,
from the top, into sixteen 800 µl fractions. Fractions
were analysed by slot- and Western-blotting after
agarose gel electrophoresis.
Agarose gel electrophoresis
Agarose gel electrophoresis was performed in 1%
(w/v) agarose gels (4). After electrophoresis, molecules
were transferred to nitrocellulose membrane by vacuum
blotting in 0.6M sodium chloride/ 0.06M sodium citrate
using a Pharmacia LKP VacuGene XL at a suction pressure
of 40mbar (4000 Pa) for 2h prior to detection of mucins
using antibodies.
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Concentration of mucin containing samples
Dilute samples were concentrated by the following
three methods:
a) They were dialysed into 6M urea containing 1-5%
PEG (polyethylene glycol powder) until the required
reduction in volume was reached.
b) They were sealed in a dialysis bag and buried under
Aquacide II powder until the required reduction in volume
was reached.
c) They were put into a small centricon concentrator
and centrifuged at 3,000 g until the required reduction in
volume was reached.
Results
It has previously been demonstrated that the benign
colonic adenoma cell line PC/AA can be converted in vitro
to adenocarcinoma (Figure 1) (1-3). The levels of MUC2
expression, at the protein level, in this adenomaadenocarcinoma sequence were compared by Western
blotting after agarose gel electrophoresis.

The cell layer extracts (Figs. 2a,b,c) and media (data
not shown) that we selected from this sequence were
subjected to agarose gel electrophoresis followed by
Western blotting. In each experiment, the same numbers
of cells (2 x 107) were analysed by using the same
techniques under the same conditions. A dramatic
decrease in the cell layer MUC2 mucins (precursor and
mature forms) and the medium MUC2 mucins (mature
forms) was detected from the benign adenoma to the
premalign and malign stages of the adenomaadenocarcinoma sequence.
The cell layer extracts and media were subjected to
isopycnic density gradient centrifugation in CsCl/4M
GuHCl as performed previously for the PC/AA8 cell line
(4). In that study, the distribution of MUC2
glycoconjugates in the density gradient of the benign
PC/AA cell layer and the corresponding medium was then
assessed using the 4F1 and LUM2-3 antibodies by
Western blotting after agarose gel electrophoresis. The
mature MUC2 molecules extracted from both the cell
layer and the medium were recovered in the density
range 1.36-1.48 g/ml. However, in the low-density

Figure 1.

Schematic representation of the
progression of the PC/AA8
adenoma derived cell line to the
tumourogenic
phenotype
adenocarcinoma (AA/C1/SB10)
in athymic mice (slightly
adapted from Williams et. al.,
1996)
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Figure 2.

Comparison of the benign
adenoma cell line (PC/AA8)
and
its
premalign
(PC/AA/C1/79)
and
adenocarcinomatous
phenotypes (PC/AA/SB10) on
SDS-agarose
gel
electrophoresis
Unreduced (U) and reduced
(R) original cell layer extracts
(a
and
b)
were
electrophoresed in a 1.0%
agarose gel with 40mM Trisacetate / 1mM EDTA, pH
8.0, containing 0.1% SDS
and
blotted
onto
nitrocellulose
membrane
prior to detection with two
anti-MUC2 mucin antibodies;
(a) 4F1 and (b) LUM2-3.
(c) Relative amounts of the
reduced cell layer MUC2
mucins of the PC/AA8,
PC/AA/C1/79
and
PC/AA/SB10 cell lines: 4F1
(

fractions of the cell layer extract we found unglycosylated
and/or partially glycosylated MUC2 precursors, which
were not detected in the medium (4). In this previous
work, we demonstrated that the 4F1 and LUM2-3
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) and LUM2-3 (

).

antibodies are quite useful probes for the precursor
forms of MUC2 and the mature MUC2 molecules,
respectively (4). We applied the same approach and the
same antibodies to the cell layers and media from the
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adenoma-adenocarcinoma sequence; however, the same
blotting experiments did not visualise MUC2 in density
gradients of the PC/AA/C1/79 and PC/AA/SB10 cell lines
as insufficient MUC2 was present (data not shown).
Therefore, we decided to pool and concentrate the top
fractions (1-6) that were expected to contain precursors
and/or partially glycosylated forms of MUC2 and the middensity fractions (9-12) that were expected to contain
mature MUC2 molecules with one of the methods
described in methods. In spite of the different
concentration techniques used for different cell lines, we

Figure 3.

had quite similar results with these three methods. The
concentrated samples were then analysed by Western
blotting (Figs. 3a,b,c,d). Although mature MUC2
molecules from both the cell layer (Figure 3a,b, lanes 34) and the medium (data not shown) were detected in the
fractions 9-12 of the density gradient on the benign cell
line PC/AA8 by the LUM2-3 only, no mature MUC2
molecules (neither cell layer nor medium) were found in
the equivalent fractions of the density gradient of the
premalign PC/AA/C1 cell line (Figure 3c, lanes 3-4) and
adenocarcinoma PC/AA/SB10 cell line (Figure 3d, lanes 3-

Comparison of the concentrated cell layers and fractions 1-6 and 9-12 from CsCl density gradient of PC/AA8, PC/AA/C1/79 and
PC/AA/SB10 cell lines on SDS-agarose gel electrophoresis
Unreduced (U) and reduced (R) original cell layer extracts (o.c. layer), fractions 9-12 and fractions 1-6 taken from density gradients of the
PC/AA8 (a, b), PC/AA/C1/79 (c), and PC/AA/SB10 (d) were concentrated (see the text) and subsequently electrophoresed in a 1.0% agarose
gel with 40mM Tris-acetate / 1mM EDTA, pH 8.0, containing 0.1% SDS and blotted onto nitrocellulose membrane prior to detection with
two anti-MUC2 mucin antibodies; LUM2-3 (a) and 4F1 (b, c, d).
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4). Precursors and/or partially glycosylated MUC2
molecules with the 4F1 antibody were detected in the cell
layers of benign adenoma cell line PC/AA8 (Figure 3b,
lanes 5-6), premalign cell line PC/AA/C1 (Figure 3c, lanes
5-6) and adenocarcinoma cell line PC/AA/SB10 (Figure
3d, lanes 5-6). The molecules detected with 4F1 in the
PC/AA/C1/79 and PC/AA/SB10 cell layers showed a
double band. The slow migrating band was not found in
the benign adenoma cell line. The origin of this band is
unknown.
Discussion
Alterations of the MUC2 expression occurring during
malignant transformation have been demonstrated in
colorectal adenocarcinomas at the mRNA level in colonic
tissues (4,6,7,16,19,20). It is not known, however, at
which step of the transformation process these
alterations become detectable (adenoma vs. carcinoma)
and how they are related to the morphogenesis of
colorectal cancer.
The early passages (8-20) of the intestinal adenoma
PC/AA cell line make copious quantities of mucins which
are both stored within and secreted by the cells
(4,15,18,20). We have previously identified the major
mucin synthesised by this cell line as the product of the
MUC2 gene (4,18). It has been established that this cell
line can be converted to the adenocarcinoma cell line in
vitro (1-3). Using the approach developed for the
identification of precursor and mature forms of MUC2
mucin from the early passages of the PC/AA cell line (4),
we followed all of the biosynthetic intermediates of
MUC2 through the adenoma-adenocarcinoma sequence
to investigate possible carcinoma-related alterations at
the protein/glycoprotein level during malignant
transformation.
Initially, the levels of MUC2 expression, at the protein
level, were compared by Western blotting after agarose
gel electrophoresis using the two MUC2-specific
antibodies 4F1 and LUM2-3, among the several colonic
cell lines representing different stages of colorectal
adenocarcinoma. The relative amounts of MUC2 indicated
that the expression and secretion of the MUC2
significantly decreased from adenoma to adenocarcinoma.
This result was in agreement with the previously
established pattern of expression of MUC2 at the mRNA
level in colonic tissues (6,23,24).
The distribution of unglycosylated and/or partially
glycosylated MUC2 precursors and mature forms were
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investigated by the combination of density gradient
centrifugation and Western blotting after agarose gel
electrophoresis. This combined approach was previously
established to define all biosynthetic intermediates of
MUC2 using the PC/AA8 benign adenoma cell line (4).
Comparison of the parental cell line PC/AA8 with the
premalignant adenoma cell line PC/AA/C1/79 and
adenocarcinoma cell line PC/AA/SB10 showed
insignificant quantities of MUC2 gene products. These
products represented precursors and/or partially
glycosylated MUC2 molecules and were present only in
the cell layers. They were detected with 4F1 and were
not reactive with LUM2-3, indicating an abnormal post
translational metabolism for MUC2. As they are not
found as stored matured mucin, and are not secreted into
the medium, we propose that these immature MUC2
molecules are being turned over within the cell and are
not secreted into the medium due to defective processing.
Aberrant glycosylation may account in part for the
abnormal pattern of MUC2 molecules found here. Others
have described cancer associated mucins with fewer and
shorter oligosaccharides for each glycosylation site
(16,25,26). One mechanism by which this could arise is
through the down regulation (abolishment) of key
glycosyltransferases involved in the several maturation
steps
necessary
to
produce
the
normally
posttranslationally modified MUC2 apoprotein. It has
been shown that this is the case for cell lines including the
malignant adenocarcinoma phenotype (PC/AA/SB10)
(25). The loss of several glycotransyltransferase
activities, including the core 3 and core 4 enzymes was
identified by Corfield et al. in the same adenomaadenocarcinoma sequence (16). This resulted in a switch
to core 1 and 2 structures, giving rise to a cancer-related
oligosaccharide pattern (16,25). The relationship of the
alteration in mucin apoprotein and glycosylation patterns
during colorectal cancer has not been assessed and is a
further mechanism giving rise to abnormal carbohydrate
patterns in cancer mucins (11,19).
This work demonstrates that using a cell culture
model of the adenoma-carcinoma sequence shows the
significantly altered expression and secretion of the major
colonic mucin MUC2 in human colorectal adenoma cells
during progression to cancer. The characterisation of
differently glycosylated forms of the MUC2 is novel and
unexpected. The implication of defective processes in the
post translational modification/processing and secretion
of MUC2 opens a new field in cancer mucin biology.
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